Analysts See GSK Quarterly Sales at £8.842 Billion
Key Facts
GSK will report third-quarter 2026 results on October 28 at 07:00 GMT, according to the company’s schedule, after analysts’ consensus estimated quarterly sales at £8.842 billion. The estimate is based on forecasts from 15 brokerages, according to the consensus page published by GSK. Information available did not include actual third-quarter results, so the consensus remains a pre-announcement estimate. The company is scheduled to hold a live call for investors and analysts at 12:00 GMT the same day. Attention is focused on whether the company will reaffirm its 2026 guidance range, which it left unchanged in its second-quarter results announcement.
The October 16 consensus put third-quarter specialty medicines sales at £3.852 billion, compared with £2.624 billion for vaccines and £2.366 billion for general medicines. In the second quarter, total sales were £8.4 billion, up 5% at actual exchange rates and 5% at constant exchange rates, according to GSK. Specialty medicines sales then rose 14% to £3.8 billion, while general medicines sales fell 9% to £2.3 billion. The divergence puts the performance of the company’s divisions at the center of the forthcoming results, with investors watching each division’s figures and comparing them with consensus estimates. Also in the second quarter, reported earnings per share fell 69% to 10.8 pence, which the company attributed to higher impairment charges and CCL charges.
In its second-quarter announcement, GSK maintained its forecast for 2026 sales growth of between 3% and 5%, and growth in core operating profit and core earnings per share of between 7% and 9%. It also announced expected dividends of 70 pence per share for the financial year. The third-quarter announcement will allow investors to assess whether the company repeats that annual guidance, alongside trends in sales and profitability across its three divisions. Chief Executive Luke Mills said the company expects to start more than 20 phase three trials during 2026, compared with a previous forecast of 10 trials. The company is targeting sales of more than £40 billion by 2031, with growth accelerating thereafter, according to an announcement in July.
GSK shares closed at $50.94 on October 27, compared with a close of $51.1 in the previous session, according to EL7 data. The move came ahead of the results announcement scheduled for the following morning GMT. The company has set February 3, 2027, as the date for publishing its fourth-quarter 2026 results, according to its filing with the U.S. Securities and Exchange Commission. The company said in the filing that the date is indicative and may be subject to change. Until then, the forthcoming third-quarter figures are the next milestone in assessing the trajectory of sales and annual guidance.